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Bladder antimuscarinics and cognitive decline in elderly patients
Daniela Claudia Mogaa,b,c,*, Erin L. Abnerb,c, Qishan Wub, Gregory A. Jichac,d
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b
Department of Epidemiology, College of Public Health, University of Kentucky, Lexington, KY, USA
c
Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, USA
d
Department of Neurology, College of Medicine, University of Kentucky, Lexington, KY, USA

Abstract

Introduction: The evidence on the impact of bladder antimuscarinics initiation on cognitive function in older adults is inconsistent.
Methods: A retrospective analysis of data from the National Alzheimer’s Coordinating Center
(NACC) on enrollees 65 years and older evaluated the association between antimuscarinic initiation
and cognitive decline. We defined decline from baseline (yes/no) for cognitive assessments included
in the NACC Uniform Data Set 2.0 battery. New users were matched on year of enrollment and time
in the cohort to randomly selected nonusers. Analyses were conducted using inverse probability of
treatment weights based on baseline propensity scores.
Results: Our analyses included 698 new users and 7037 nonusers. The odds ratio (OR) and 95% confidence interval for cognitive decline in users as compared to nonusers was 1.4 (1.19–1.65) for Mini–
Mental State Examination (MMSE), and 1.21 (1.03–1.42) for Clinical Dementia Rating; in addition,
the odds of decline were 20% higher in users compared to nonusers for semantic memory/language
and executive function. The effect estimate for MMSE was 1.94 (1.3–2.91) for those with mild cognitive impairment, 1.26 (0.99–1.62) in those with normal cognition, and 1.44 (1.04–1.99) in those with
dementia at baseline.
Discussion: Our results show that antimuscarinic initiation is associated with cognitive decline and
raise questions about their use, especially in those with impaired cognition.
Ó 2017 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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1. Introduction
The cholinergic system in the brain plays an important
role in working memory, attention, awareness, psychomotor
speed, and selection of relevant stimuli from the environment [1]. By blocking cholinergic receptors in the central
nervous system (CNS), drugs with anticholinergic activity
could potentially cause undesirable effects on these important cognitive functions, depending on the drug bioavailability and metabolism, as well as its ability to cross the
blood–brain barrier [2,3]. Changes in the acetylcholine-
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mediated neurotransmission and the increased permeability
of the blood–brain barrier caused by aging inflate the risk of
CNS adverse effects of anticholinergic drugs. Similar effects
are the result of different comorbidities (e.g., diabetes mellitus, Alzheimer’s disease [AD], vascular dementia), which
are also more prevalent in the elderly population [4–6].
Previous studies showed that drugs with anticholinergic
properties could result in cognitive decline and even
precipitate dementia in older adults [7,8]. Moreover, a
recent prospective cohort study investigating the effect of
cumulative anticholinergic exposure demonstrated an
increased risk of dementia with higher use of
anticholinergics in adults aged 65 years and older [9].
Bladder antimuscarinics (referred to as antimuscarinics
hereafter), the main pharmacological option for treating
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urge and mixed urinary incontinence, are among the most
commonly used drugs with anticholinergic properties in
the elderly [9]. Of the available antimuscarinics, the most
frequently used by patients is oxybutynin, a nonselective
agent that can bind to receptors throughout the body,
including CNS [9]. Previous studies investigating the potential role of antimuscarinics in causing cognitive decline in
older adults included a small number of patients, measured
cognitive performance with scales less sensitive to longitudinal change, or followed participants for a short period and
led to inconclusive results. Some of the studies suggested
that in patients with AD, antimuscarinics produce cognitive,
behavioral, and physiological changes [10,11], but other
studies failed to support these findings [12]. The primary
objective of our study was to further evaluate the association
of antimuscarinic initiation with cognitive decline in older
adults by using the rich data collected as part of the ongoing
National Alzheimer’s Coordinating Center (NACC) cohort
and to address some of the limitations of previous studies.
2. Methods
2.1. Setting
We conducted a retrospective evaluation using data
collected as part of the prospective NACC cohort. Data available from the Uniform Data Set (UDS) between September
1, 2005 and December 31, 2013 were used to identify
new antimuscarinic users [13] and nonusers as controls and
conduct all of the analyses described in the following.
2.2. Participants
A description of the NACC cohort, its eligibility criteria,
and data collection are available elsewhere [14–17]. In
summary, NACC was established in 1999 with the purpose
of facilitating research related to AD. This cohort includes
not only patients with AD and related disorders but also
cognitively normal subjects and those with mild cognitive
impairment (MCI). Beginning in 2005, UDS data were
collected through standardized evaluations of enrollees
from National Institute on Aging–funded Alzheimer’s
Disease Centers (ADC). Each ADC has its own
recruitment protocol, and participants are recruited
through clinician or self-referral (patients or family members), or through active community recruitment strategies.
Of the 32,532 participants enrolled in NACC between
2005 and beginning of 2016, about 89% were 60 years or
older, 80% were white, 70% had 12 or more years of education, 37% had normal cognition at enrollment, about 21%
had MCI, and about 37% had dementia. In addition to the
ADC-specific inclusion/exclusion criteria, the eligibility
criteria for our investigation included (1) participants
enrolled on or after September 1, 2005 with a minimum of
one follow-up visit; (2) age 65 years and older at the
visit when antimuscarinic use was first reported (or the
equivalent visit for nonusers—see the following for

additional information regarding nonusers selection); (3)
with medication data available at all visits, and (4) with no
antimuscarinics reported at enrollment. We excluded participants with non-MCI or non–AD-related cognitive impairment, specifically (1) cognitive status categorized as
“impaired not mild cognitive impairment”; (2) frontotemporal dementia; (3) primary progressive aphasia; (4) progressive supranuclear palsy; (5) corticobasal degeneration; (6)
Huntington’s disease; (7) prion disease; (8) Down’s syndrome; (9) CNS neoplasm; (10) traumatic brain injury;
(11) hydrocephalus; (12) alcohol-related dementia; (13) dementia of undetermined etiology. A flow diagram to describe
the participants’ selection process and the groups included in
the analyses is depicted in Fig. 1.
Exposure to antimuscarinics was identified from the selfreported data collected at enrollment and yearly thereafter
using the “brown bag” medication review approach (i.e.,
the participant or a family member were asked to bring all
current medications to the research assessment) on prescription and over-the-counter medications for the two-week
window preceding the index date [15]. Antimuscarinic exposure was measured as antimuscarinics yes/no by identifying
at least one mention of the following medications: oxybutynin, tolterodine, flavoxate, hyoscyamine, darifenacin,
trospium, solifenacin, fesoterodine, propantheline. Antimuscarinic exposure was further categorized based on muscarinic receptor selectivity: nonselective antimuscarinics
(oxybutynin, tolterodine, flavoxate, hyoscyamine, trospium,
fesoterodine, propantheline) and M3 selective antimuscarinics (darifenacin or solifenacin). When exposure to more
than one antimuscarinic was reported, exposure category
was assigned as nonselective in the presence of at least
one nonselective drug. Antimuscarinic users were considered prevalent users if antimuscarinic exposure was reported
at enrollment and incident (new) users if exposure was first

Fig. 1. Inclusion/exclusion cascade and study groups. Abbreviations: BAM,
bladder antimuscarinics; IPTW, inverse probability of treatment weights;
MCI, mild cognitive impairment; NACC, National Alzheimer’s Coordinating Center.
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Fig. 2. Figure shows percent with cognitive decline in antimuscarinic users and nonusers stratified by baseline cognitive status. Top panels include unadjusted
analyses; Bottom panels include adjusted (weighted) analyses.

reported at one of the follow-up visits. Prevalent users were
excluded from further analyses.
2.3. Outcome description
Cognitive function was measured based on the information collected at follow-up UDS visits. From the comprehensive cognitive evaluation conducted as part of the
cohort, we selected our measures of interest based on
the evidence from prior research to suggest areas potentially impacted by medications with anticholinergic properties in general, and therefore antimuscarinics. Our
outcomes included two measures of global cognitive status—Mini–Mental State Examination (MMSE) [18] and
Clinical Dementia Rating (CDR) [19] global score. In
addition, we also evaluated the association between antimuscarinic initiation and decline in clinical diagnosis status by assessing the likelihood of decline from normal to
MCI or dementia, and from MCI to dementia within 1
year from baseline. Furthermore, specific cognitive domains were evaluated using the following measures: (1)
memory, orientation, and judgment domain scores from
CDR; (2) semantic memory and language using category
fluency tests (Animals and Vegetables) and Boston
Naming Test; (3) psychomotor speed using WAIS-R
Digit-Symbol Substitution and the Trail Making Test
Part A; and (4) executive function using the Trail Making
Test Part B. Detailed descriptions of these tests, including
information about score range and interpretation for the

NACC ADC cohort, are available elsewhere [17]. Decline
was identified as a dichotomous variable and was defined
considering the scoring algorithm for each cognitive
outcome. Specifically, a participant was categorized as
experiencing cognitive decline from baseline in case of a
higher score at the follow-up visit (CDR global score,
memory, orientation, and judgment domain scores from
CDR), or a lower score at follow-up visit (MMSE, Animals and Vegetables, Boston Naming Test), or a longer
time for completion at follow-up as compared to baseline
(WAIS-R Digit-Symbol Substitution, Trail Making Test
Part A, Trail Making Test Part B), as compared to their
score (or time) at baseline. We also coded decline if the
score was in the valid range at baseline but was missing
due to “cognitive/behavior problem” at follow-up. In addition, we conducted sensitivity analyses to test the robustness of our outcome definition (i.e., cognitive decline)
by excluding those with missing data and using a more
conservative approach that considered decline in the presence of a clinically meaningful change based on the standard deviations for cognitively intact older adults reported
in a previous study using NACC data [17]. Specifically, we
considered two additional definitions, one where decline
was defined based on a minimum change equal to half
the reported standard deviation, and one where decline
was defined based on a minimum change equal to one reported standard deviation. Because the reported standard
deviations contained decimals, we rounded up to the
next whole point to define decline.

Downloaded for Anonymous User (n/a) at University of Kentucky from ClinicalKey.com by Elsevier on April 05, 2018.
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2.4. Statistical analysis
Analyses were conducted after the comparison group of
nonusers was selected, and we applied all eligibility criteria
for both groups. For each new user, we randomly selected
10 nonusers that were matched by year of enrollment and
time since enrollment (visit year). Baseline was defined
as the prior UDS assessment (i.e., last assessment before
the first one reporting antimuscarinic use, or the equivalent
for the nonusers group). We evaluated group differences
between antimuscarinic users and nonusers at baseline using chi-square analysis (or Fisher’s exact test where appropriate) for categorical variables, and t-tests for continuous
variables.
For the main analyses, the propensity score (PS)
method was used to address treatment selection bias and
to balance observed baseline covariates between the study
groups. The PS for each participant was estimated through
logistic regression as the probability of starting treatment
with an antimuscarinic during study period (i.e., report
antimuscarinic use during a UDS evaluation) based on
their characteristics measured at baseline from the standardized NACC data collection based on self-reported information or proxy respondents. The logistic regression
model to predict antimuscarinic initiation and calculate
PS included variables related to antimuscarinic use and
also variables for which empirical evidence exists to
support their impact on cognitive function [20,21].
Specifically,
the
model
included
demographic
characteristics (age, race, sex, education), living
situation, indicators for each recruiting center (ADC),
year at enrollment, year at assessment, body mass index
(BMI), lifestyle-related risk factors (hypercholesterolemia,
alcohol use, smoking), urinary and fecal incontinence status, cognitive status (i.e., normal, MCI, or dementia), level
of independence, comorbidities (cardiovascular disease,
congestive heart failure, stroke, transient ischemic attack,
Parkinson’s disease, hypertension, diabetes, recent depression episodes, psychiatric disorders), other medications
used (antiadrenergic agents, beta blockers, diuretics, calcium channel blocking agents, angiotensin-converting
enzyme inhibitors, antidepressants, antipsychotic agents,
anxiolytic, sedative, or hypnotic agents, antiparkinsonian
agents, medications approved by the Food and Drug
Administration for the treatment of AD’s cognitive symptoms [i.e., memantine or cholinesterase inhibitors], and total number of medications reported at visit), and
anticholinergic load measured using the anticholinergic
drug scale [22]. When calculating propensity scores, to
address the issues of missing data for some of the categorical variables included in the model, missing values were
treated as a separate category.
The association between antimuscarinic exposure and
cognitive outcomes was measured based on each patient’s
change in score from baseline. The odds ratios with 95%
confidence limits for cognitive decline associated with

antimuscarinic initiation were calculated using inverse probability of treatment weights (IPTWs) with stabilized weights
based on the PS for initiating antimuscarinics and trimming
nonoverlapping regions of the PS distribution [23,24].
Analyses were conducted for all antimuscarinic users and
also after restricting the new users group to those treated
with nonselective agents. For a clinical interpretation of
the results, we also calculated the number needed to treat
to cause decline for the overall cognitive performance
measures [25]. As an exploratory analysis, we evaluated
whether the association of antimuscarinics and cognitive
decline measured through MMSE was different by cognitive
status at baseline (normal, MCI, or dementia), for all antimuscarinics users and also restricted to nonselective
antimuscarinics.

3. Results
Of the 29,004 participants enrolled in the NACC cohort
between September 1, 2005 and December 31, 2013, 2075
reported antimuscarinic use during follow-up. Of these,
787 participants did not report antimuscarinics at enrollment, and 698 met all the eligibility criteria for the study
and were considered new antimuscarinic users for our analyses (Fig. 1). About 70% of users reported a nonselective
antimuscarinic, most commonly oxybutynin and tolterodine
(about 40% of the nonselective antimuscarinics for each). Of
those using M3 selective antimuscarinics, about 66% used
solifenacin. Of the 7870 nonusers randomly selected after
matching by year of enrollment and year of first antimuscarinic report, 7037 met the inclusion/exclusion criteria and
were included in our analyses (Fig. 1).
The magnitude of cognitive decline from baseline as
evaluated through MMSE and CDR was larger in antimuscarinic users as compared to nonusers (Table 1 and Fig. 2).
When antimuscarinic users and nonusers were compared at
baseline, several significant differences were noted in the
unadjusted analyses (Table 1). New users were mostly
women, older, less likely to live in a single family residence, and more likely to need assistance. Nonusers were
healthier, with lower BMI and fewer comorbid conditions
(less likely to have diabetes, Parkinson’s disease, depression, other psychiatric diagnosis, or active fecal incontinence), were taking fewer drugs, and had a lower
anticholinergic load. New users were more likely to have
hallucinations or agitation indicated at baseline and were
more frequently cognitively impaired (Table 1 and
Supplementary Table 1). After calculating the PS for
each participant and applying weights through the IPTW
method, the groups included in the analyses were balanced
on the measured confounders (Supplementary Table 2).
Similar to the unadjusted results, in the IPTW analyses
that accounted for baseline differences between groups,
new users were more likely to show statistically significant cognitive decline in the overall cognitive status

Downloaded for Anonymous User (n/a) at University of Kentucky from ClinicalKey.com by Elsevier on April 05, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.

D.C. Moga et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 3 (2017) 139-148

143

Table 1
Baseline and follow-up characteristics in bladder antimuscarinics users and nonusers
Characteristic
Baseline
Time from enrollment (days): mean (SD)
Year of enrollment: n (%)
2005
2006
2007
2008
2009
2010
2011
2012
Age: mean (SD)
Male: n (%)
Race: n (%)
White
Black
Other
Education: n (%)
High school or less
College degree
Graduate degree
Living situation: n (%)
Lives alone
Lives with spouse or partner
Lives with relative or friend
Lives with group
Other or unknown
Residence type: n (%)
Single family residence
Retirement community
Assisted living/boarding home/adult family home
Skilled nursing facility/nursing home
Unknown
Level of independence: n (%)
Able to live independently
Requires some assistance with complex activities
Requires some assistance with basic activities
Completely dependent
BMI category: n (%)
Normal
Overweight
Obese
Underweight
Unknown
Smoking history—100 lifetime cigarettes: n (%)
Alcohol abuse: n (%)
Comorbidities: n (%)
Hypercholesterolemia
Cardiovascular disease
Diabetes
Parkinson’s disease
Depression
Psychiatric diagnosis
Stroke
Urinary incontinence (active)
Fecal incontinence (active)
Number of medications reported at visit: mean (SD)
Anticholinergic burden: mean (SD)
Other medications: n (%)
Antiadrenergic agent
Beta-adrenergic blocking agent
Angiotensin-converting enzyme inhibitor

Nonusers (N 5 7037)

New users (N 5 698)

463.1 (550.1)

425.9 (535.5)

845 (12.01)
2855 (40.57)
1448 (20.58)
696 (9.89)
521 (7.40)
390 (5.54)
186 (2.64)
96 (1.36)
76.98 (7.63)
2993 (42.53)

87 (12.46)
279 (39.97)
149 (21.35)
62 (8.88)
51 (7.31)
39 (5.59)
20 (2.87)
11 (1.58)
77.88 (7.15)
289 (41.40)

5784 (82.19)
831 (11.81)
422 (6.00)

584 (83.67)
82 (11.75)
32 (4.58)

2054 (29.19)
2883 (40.97)
2100 (29.84)

199 (28.51)
282 (40.40)
217 (31.09)

1903 (27.04)
4171 (59.27)
655 (9.31)
129 (1.83)
179 (2.54)

202 (28.94)
412 (59.03)
55 (7.88)
16 (2.29)
13 (1.86)

6051 (85.99)
585 (8.31)
177 (2.52)
113 (1.61)
111 (1.58)

565 (80.95)
80 (11.46)
31 (4.44)
6 (0.86)
16 (2.29)

4546 (64.60)
1486 (21.12)
733 (10.42)
272 (3.87)

394 (56.45)
198 (28.37)
87 (12.46)
19 (2.72)

2356 (33.48)
2512 (35.70)
1332 (18.93)
86 (1.22)
751 (10.67)
3289 (46.74)
355 (5.04)

210 (30.09)
231 (33.09)
162 (23.21)
8 (1.15)
87 (12.46)
318 (45.56)
35 (5.01)

4016 (57.07)
555 (7.89)
916 (13.02)
134 (1.90)
1923 (27.33)
360 (5.12)
428 (6.08)
408 (5.80)
460 (6.54)
5.68 (3.72)
0.66 (1.12)

399 (57.16)
56 (8.02)
110 (15.76)
45 (6.45)
233 (33.38)
51 (7.31)
51 (7.31)
59 (8.45)
60 (8.60)
6.44 (4.19)
0.91 (1.34)

598 (8.50)
1587 (22.55)
1357 (19.28)

93 (13.32)
174 (24.93)
138 (19.77)
(Continued )
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Table 1
Baseline and follow-up characteristics in bladder antimuscarinics users and nonusers (Continued )
Characteristic

Nonusers (N 5 7037)

Antidepressant
Antipsychotic agent
Anxiolytic, sedative, or hypnotic agent
Antiparkinson agent
Medication for Alzheimer’s disease symptoms
Diuretic
Calcium channel blocking agent
Hallucinations: n (%)
Delusions: n (%)
Agitation
Cognitive status: n (%)
Normal
MCI
Dementia
Mini–Mental State Examination: mean (SD)
All
Baseline cognitive status: normal
Baseline cognitive status: MCI
Baseline cognitive status: dementia
Mini–Mental State Examination: n (%)
Normal
Mild impairment
Moderate impairment
Severe impairment
Missing
Clinical Dementia Rating Global score: n (%)
No impairment
Questionable impairment
Mild impairment
Moderate impairment
Severe impairment
Follow-up
Mini–Mental State Examination: mean (SD)
All
Baseline cognitive status: normal
Baseline cognitive status: MCI
Baseline cognitive status: dementia
Mini–Mental State Examination: n (%)
Normal
Mild impairment
Moderate impairment
Severe impairment
Cognitive or behavioral problems
Missing
Clinical Dementia Rating Global score: n (%)
No impairment
Questionable impairment
Mild impairment
Moderate impairment
Severe impairment
Cognitive decline (Mini–Mental State Examination): n (%)
Including decline based on information regarding missing
Including only those with available data
Baseline cognitive status: normal
Baseline cognitive status: MCI
Baseline cognitive status: dementia

1732 (24.61)
286 (4.06)
676 (9.61)
244 (3.47)
2134 (30.33)
1280 (18.19)
1096 (15.57)
242 (3.44)
555 (7.89)
1260 (17.91)

227 (32.52)
33 (4.73)
102 (14.61)
69 (9.89)
249 (35.67)
128 (18.34)
121 (17.34)
32 (4.58)
56 (8.02)
150 (21.49)

3269 (46.45)
1306 (18.56)
2462 (34.99)

259 (37.11)
151 (21.63)
288 (41.26)

25.24 (6.12)
28.82 (1.54)
26.88 (2.65)
19.42 (7.01)

New users (N 5 698)

25.46 (5.09)
28.82 (1.40)
26.97 (2.74)
21.52 (5.56)

3985 (56.63)
1646 (23.39)
833 (11.84)
266 (3.78)
307 (4.36)

363 (52.01)
216 (30.95)
77 (11.03)
13 (1.86)
29 (4.15)

3119 (44.32)
2055 (29.20)
1168 (16.60)
460 (6.54)
235 (3.34)

249 (35.67)
251 (35.96)
143 (20.49)
48 (6.88)
7 (1.00)

24.70 (6.64)
28.72 (1.72)
26.22 (3.33)
17.72 (7.17)

24.26 (6.21)
28.68 (1.53)
25.98 (3.29)
19.04 (6.42)

3730 (53.01)
1388 (19.72)
973 (13.83)
350 (4.97)
83 (1.18)
513 (7.29)

321 (45.99)
173 (24.79)
124 (17.77)
23 (3.30)
6 (0.86)
51 (7.31)

3003 (42.67)
1777 (25.25)
1110 (15.77)
718 (10.20)
429 (6.10)

227 (32.52)
208 (29.80)
147 (21.06)
86 (12.32)
30 (4.30)

3600 (51.15)
2972 (46.71)
1137 (34.78)
668 (51.15)
1795 (72.91)

416 (59.60)
356 (56.15)
101 (39.00)
92 (60.93)
223 (77.43)

Abbreviations: SD, standard deviation; MCI, mild cognitive impairment.
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(Table 2) as measured by MMSE (odds ratio [OR] 5 1.4,
95% confidence interval [CI]: 1.19–1.65) and CDR
(OR 5 1.21, 95% CI: 1.03–1.42). In addition, the association with decline on different specific cognitive domains
was statistically significant in the areas of memory
(OR 5 1.27, 95% CI: 1.05–1.52) and orientation
(OR 5 1.25, 95% CI: 1.04–1.51) domains of CDR, semantic memory/languages as measured by category
fluency tests (Vegetable Naming: OR 5 1.23, 95% CI:
1.05–1.44), and executive function as measured by
the Trail Making Test Part B (OR 5 1.23, 95% CI:
1.08–1.51). Our sensitivity analyses including the more
conservative outcome definitions supported the results of
our main analyses (Supplementary Table 3). In our
exploratory analyses, when evaluating the association
with decline on MMSE stratified by cognitive status at
baseline, although not statistically significantly different,
the effect estimate was larger for those with MCI at baseline (OR 5 1.94, 95% CI: 1.3–2.91), then in those with
normal cognition (OR 5 1.26, 95% CI: 0.99–1.62), or dementia (OR 5 1.44, 95% CI: 1.04–1.99). In addition, the
effect estimate for MMSE decline was larger when analyses were restricted to new users of nonselective antimuscarinics (Table 2). The estimated numbers needed to
treat to produce a harmful effect (NNH) (i.e., cognitive
decline) in one participant were NNH 5 22 (95% CI:
12–142) for decline in the CDR global score, and
NNH 5 13 (95% CI: 9–24) for decline in MMSE,
with the smallest number in those with MCI at
baseline: NNH 5 7 (95% CI: 3–16) (Table 3). These results indicate that for every 22 patients treated with

145

antimuscarinics, one would experience decline in the
CDR global score; similarly, for every 13 patients treated
with antimuscarinics, or for every 7 patients with MCI at
baseline treated with antimuscarinics, one would experience decline as measured by MMSE.
4. Discussion
Using the rich data collected as part of the ongoing
NACC cohort, our study evaluated the association between
antimuscarinic initiation and odds of decline on various
cognitive measures in older adults. Our analyses showed
that, after controlling for baseline differences between
groups, participants who initiated an antimuscarinic were
statistically significantly more likely to exhibit cognitive
decline as compared to nonusers. Specifically, antimuscarinic initiators experienced decline when cognitive function
was measured with overall measures, and also they showed
decline in cognitive domains for which there is biological
plausibility for such an effect. To further investigate this association, we investigated and identified a potentially stronger negative effect on cognitive function when restricting
our analyses to those using nonselective antimuscarinics.
In terms of the clinical impact, a previous study estimated
that 32 patients (95% CI: 17–125) needed to be treated to
obtain improvement in urinary incontinence in one patient
after 90 days of treatment [12]. In this context, our estimates for the NNH for different cognitive outcomes are
striking and raise important concerns with these drugs by
suggesting that we need to treat only a small number of patients to detect cognitive decline in one, and more patients

Table 2
Cognitive decline (any decline) associated with bladder antimuscarinics use
Cognitive domain

Cognitive test

Overall cognitive status

Mini–Mental State Examination
Overall
By baseline cognitive function
Normal
Mild cognitive impairment
Dementia
Clinical Dementia Rating
Global score
Memory
Orientation
Judgment
Category fluency
Animals
Vegetables
Boston
WAIS-R Digit Symbol
Trail A
Trail B

Semantic memory/language

Psychomotor speed
Executive function

IPTW*—all users, OR (95% CI)

IPTW*—NS users, OR (95% CI)

1.4 (1.19–1.65)

1.54 (1.26–1.89)

1.26 (0.99–1.62)
1.94 (1.3–2.91)
1.44 (1.04–1.99)

1.42 (1.05–1.92)
1.73 (1.03–2.92)
1.76 (1.17–2.67)

1.21 (1.03–1.42)
1.27 (1.05–1.52)
1.25 (1.04–1.51)
1.08 (0.9–1.31)

1.22 (1.01–1.48)
1.32 (1.05–1.65)
1.36 (1.09–1.7)
1.12 (0.88–1.41)

1.1 (0.94–1.29)
1.23 (1.05–1.44)
1.13 (0.96–1.32)
1.04 (0.88–1.23)
1.11 (0.95–1.31)
1.23 (1.08–1.51)

1.14 (0.94–1.39)
1.19 (0.97–1.44)
1.17 (0.96–1.42)
1.09 (0.89–1.33)
1.16 (0.95–1.42)
1.16 (0.95–1.43)

Abbreviations: IPTW, inverse probability of treatment weights; OR, odds ratio; CI, confidence interval; NS, nonselective; ADC, Alzheimer’s Disease Centers.
*Propensity score used to calculate stabilized weights for IPTW included indicators for each ADC, year of enrollment and time from enrollment, sociodemographic information (age, sex, race, education, residence type, and living situation), level of dependency, behavioral risk factors (body mass index, alcohol,
smoking), comorbidities (urinary and fecal incontinence, cardiovascular conditions, diabetes, Parkinson’s disease, depression, stroke, psychiatric diagnosis),
number of and other medications used, anticholinergic burden.
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Table 3
Number needed to harm in relationship to bladder antimuscarinic use
Cognitive test
y

CDR Global score
MMSEz
All
Baseline cognitive status: normal
Baseline cognitive status: MCI
Baseline cognitive status: dementia

NNH* (95% CI); all users

NNH (95% CI); NS users

22 (12–142)

21 (14–422)

13 (9–24)
19 (9–442)
7 (3–16)
16 (9–131)

10 (7–18)
13 (7–90)
8 (5–136)
11 (7–34)

Abbreviations: NNH, number needed to harm; CI, confidence interval; NS, nonselective; CDR, Clinical Dementia Rating; MMSE, Mini–Mental State
Examination; MCI, mild cognitive impairment; OR, odds ratio.
*NNH derived from OR estimates [25].
y
From normal to either MCI or dementia, or from MCI to dementia.
z
At least one-point decrease in MMSE score.

to see improvement in one. Importantly, the potential for an
even larger effect if antimuscarinics are prescribed to patients with MCI are to be considered in the clinical
decision-making process.
Our results are in line with other studies that previously
investigated the relationship between antimuscarinic initiation and cognitive decline. A single-blind crossover design
study on nine patients with AD measured MMSE, the Neuropsychiatric Inventory, and the Memory and Behavior Problems Checklist on and off antimuscarinics and showed that
antimuscarinics produce cognitive, behavioral, and physiological changes; moreover, the study showed that antimuscarinics with stronger anticholinergic activity were
associated with greater decline in MMSE [10]. Similarly, a
randomized clinical trial on 150 healthy volunteers found
that antimuscarinics decreased delayed recall and suggested
differences in effects for different antimuscarinics depending on their selectivity for different muscarinic receptors;
specifically, the study identified significantly more important
impairment associated with the nonselective antimuscarinics (oxybutynin) as compared to the bladder-selective
one (darifenacin) [11]. A retrospective cohort study conducted in a nursing home population evaluated the long-term
functional and cognitive outcomes in elderly that received
antimuscarinics concomitant with cholinesterase inhibitors
and showed that those taking both medications had greater
rates of functional decline as compared to those who
received cholinesterase inhibitors alone [26].
Our study has important strengths as compared to these
previous studies investigating the association between antimuscarinics and cognitive decline. Our investigation
included more new users of antimuscarinics from a large
cohort of participants with different levels of cognitive function. All of the participants underwent extensive cognitive
testing using well-established and validated instruments.
Moreover, the testing was independent of antimuscarinic
use in our study; therefore, differential misclassification
or bias in our analyses is of lesser concern. In addition, our
analyses were conducted after careful consideration of confounding by using the IPTW approach to balance study
groups [27,28].

Given the nature of the data available and the issues
arising with repeated testing in longitudinal studies (i.e.,
practice effects), our study has some limitations. Repeated
testing and potential for learning effects, or ceiling/flooring
effects would potentially bias our results and underestimate
the true effect size [29,30]. With data collection scheduled
at enrollment and yearly after, and given that the question
on medication use asks about current medications taken by
the participant (i.e., all medications taken within 14 days of
the visit), we could not ascertain the exact date for
antimuscarinic initiation, and, therefore, the duration of
exposure to antimuscarinics for our users group. In
addition, some of the BAM users may have been
misclassified as nonusers in the situation in which they
started and stopped treatment between two consecutive
study visits. Finally, we were able to discern between
selective and nonselective antimuscarinics; however, we
could not differentiate between immediate-release and
extended-release nonselective antimuscarinic formulations.
Nevertheless, the bias resulting from these study design
issues would not change the interpretation for our results,
but would rather provide an underestimate for the true antimuscarinic effect on cognition. For instance, patients misclassified as nonusers, would be more likely those
experiencing adverse effects soon after antimuscarinic
initiation or those not tolerating these medications [31];
as a result, we can make the assumption that those participants would also be more likely to experience cognitive
outcomes (i.e., decline) and be analyzed in the nonusers
group, thus biasing the results toward the null. Similarly,
our inability to restrict our analyses to those using
immediate-release formulations prevented us from seeing
a larger effect to that seen after restriction to nonselective
antimuscarinics. The potential for residual confounding in
our study remains given our inability to discern whether
antimuscarinic initiation was due to treatment of incontinence as a prodromal symptom of cognitive decline. We
addressed this issue by incorporating a measure of
incontinence severity in our propensity score calculation
that allowed for balance between the groups. Another limitation of our study is driven by the population recruited in
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the NACC cohort. Given the recruitment strategies that
differ among ADCs, participants enrolled in this cohort
are not necessarily a representative random sample for
the entire population of patients with MCI or dementia,
or for elderly with no cognitive impairment. Participants
in the NACC cohort, and therefore in our study, are in general more educated, have higher income, and more likely to
receive care in academic hospitals and clinics. Therefore,
the generalizability of these findings to all communitydwelling elderly may be limited. Replication of our results
in independent samples is needed.
In conclusion, our results support the growing evidence
for the association between antimuscarinic initiation and
cognitive decline in patients aged 65 years and older.
Importantly, our data show that patients with MCI might
be more sensitive to these antimuscarinic effects. Considering our findings suggesting that one would have to
treat fewer individuals to cause an adverse outcome
than to achieve the hoped-for benefit, prescribers
should consider this potential effect when contemplating
antimuscarinic initiation for their elderly patients
with urinary incontinence and should always weigh
the risks and the benefits of such treatment for each patient
individually.
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RESEARCH IN CONTEXT

1. Systematic review: We conducted a standard literature
review using PubMed to identify studies investigating
the association between bladder antimuscarinics and
cognitive decline in elderly patients. These previous
studies led to inconclusive results and they have important limitations, including small sample size, short
follow-up, or measuring cognitive function with scales
less sensitive to longitudinal change.
2. Interpretation: We demonstrated a statistically significant association between bladder antimuscarinic
initiation and different measures of cognitive function in adults aged 65 years and older; specifically,
our study showed that antimuscarinic initiation was
associated with worsening cognition. In addition,
we investigated association with specific cognitive
outcomes for which biologic plausibility supports
such effects. Importantly, our data showed that patients with mild cognitive impairment might be
more sensitive to these effects.
3. Future directions: Further investigations are needed
to explore the potential for a differential effect of
different types of BAM to allow for proper disease
management when medication is needed in this population.
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